Member Comments are provided by individuals and reflect their personal opinions only. Under NO circumstances should you act on any advice or opinion posted in this forum.  ALWAYS check with your personal physician before taking any action regarding your health! MedHelp International and our partners, sponsors and affiliates have no obligation to monitor any comments posted on this site, or the content and/or accuracy of such exchanges. MedHelp International does not endorse the views of any user.
 | 

ENHANCE trial does not prove lipid lowering agents fail the general population

by Enoch Choi, MD, Jan 16, 2008 11:00AM
Could you please comment on why the FDA has not issued an official advisory, but media is hyping and misleading the public regarding results from the ENHANCE trial (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia).  Merck and Schering-Plough submitted this for presentation as an pre-publication abstract at the American College of Cardiology meeting in March 2008.

Can you confirm these that I could dig up:

    * No difference between patients treated with ezetimibe/simvastatin 10/80 mg (Vytorin) versus patients treated with simvastatin 80 mg alone, over a two year period, for the primary endpoint of the mean change in intima-media thickness (IMT) measured at three sites in the carotid arteries. Carotid ultrasound studies are seen as reliable surrogate markers and predictive of future cardiac events.  There was a NON-statistically significant difference in wall thickness (p=0.29).

    * The Heterozygous Familial Hypercholesterolemia (HFH) population studied had baseline LDL measurements > 300 mg/dL. These patients make up 0.2% of the general population and are NOT representative of the typical patient receiving medication for hyperlipidemia.

    * Since conclusive evidence of ezetimibe's true effect is not available until studies on the general population with more power are published, maximizing statin dosing whenever possible is warranted for many patients with hypercholesterolemia.  Niacin or colesevelam (Welchol) are  alternatives to consider for statin intolerant patients.

http://www.merck.com/newsroom/press_releases/product/2008_0114.html
Member Comments

by Momto3, Jan 16, 2008 12:43PM
To: Dr. Choi
I'm thinking that you want to direct your questions to one of the cardiologists.  To the right, there are separate links for questions to the doctor(s) and questions/comments to the community at large.

Connie

by Enoch Choi, MD, Jan 17, 2008 01:23AM
To: Momto3
Oh!  darnit.  i don't think i can since there's no free questions left today.  shucks.

by Momto3, Jan 17, 2008 07:47AM
To: Dr. Choi
Try the Interventional Cardiology board : )
Post Comment
To
Comment
Post Comment
Recent Activity
Me967 { :~/ -::::: Has a special prayer request for a 14 yr old bo...
chasha33 commented on Today
3 hrs ago
Flycaster305 is finding the Christmas Spirit.
April2 it's one thing after another!
April2 commented on Today
4 hrs ago
stormy128 joined this community
Welcome them!
5 hrs ago
TrudieC commented on Today
6 hrs ago
stubby226 commented on Today
6 hrs ago
RSS Expert Activity
EVIDENCE-BASED APPROACH TO NEUTER S...
Dec 15 by Arnold L Goldman, D.V.M.
HOW DO/SHOULD DOCTORS THINK ABOUT T...
Dec 15 by Arnold L Goldman, D.V.M.
Simple tool to Assess your Risk for...
Dec 14 by Lee Kirksey, MD
Community Members